Format

Send to

Choose Destination
Ultrasound Obstet Gynecol. 2017 Jun;49(6):751-755. doi: 10.1002/uog.17399. Epub 2017 May 14.

Accuracy of competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation.

Author information

1
Harris Birthright Centre for Fetal Medicine, King's College Hospital, London, UK.
2
Institute of Health Research, University of Exeter, Exeter, UK.
3
Chinese University of Hong Kong, Hong Kong, China.
4
Medway Maritime Hospital, Gillingham, UK.
5
Homerton University Hospital, London, UK.
6
North Middlesex University Hospital, London, UK.
7
Centre Hospitalier Universitaire Brugmann, Université Libre de Bruxelles, Brussels, Belgium.
8
Hospital Universitario San Cecilio, Granada, Spain.
9
Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain.
10
Attikon University Hospital, Athens, Greece.
11
Ospedale Maggiore Policlinico, Milan, Italy.
12
Hospiten Group, Tenerife, Canary Islands, Spain.
13
Southend University Hospital, Essex, UK.

Erratum in

Abstract

OBJECTIVE:

To examine the diagnostic accuracy of a previously developed model for prediction of pre-eclampsia (PE) by a combination of maternal factors and biomarkers at 11-13 weeks' gestation.

METHODS:

This was a prospective first-trimester multicenter study of screening for PE in 8775 singleton pregnancies. A previously published algorithm was used for the calculation of patient-specific risk of PE in each individual. The detection rates (DRs) and false-positive rates (FPRs) for delivery with PE < 32, < 37 and ≥ 37 weeks were estimated and compared with those for the dataset used for development of the algorithm.

RESULTS:

In the study population, 239 (2.7%) cases developed PE, of which 17 (0.2%), 59 (0.7%) and 180 (2.1%) developed PE < 32, < 37 and ≥ 37 weeks, respectively. With combined screening by maternal factors, mean arterial pressure, uterine artery pulsatility index and serum placental growth factor, the DR was 100% (95% CI, 80-100%) for PE < 32 weeks, 75% (95% CI, 62-85%) for PE < 37 weeks and 43% (95% CI, 35-50%) for PE ≥ 37 weeks, at a 10% FPR. These DRs were similar to the estimated rates for the dataset used for development of the model: 89% (95% CI, 79-96%) for PE < 32 weeks, 75% (95% CI, 70-80%) for PE < 37 weeks and 47% (95% CI, 44-51%) for PE ≥ 37 weeks.

CONCLUSION:

Assessment of a combination of maternal factors and biomarkers at 11-13 weeks provides effective first-trimester screening for preterm PE. Copyright © 2017 ISUOG. Published by John Wiley & Sons Ltd.

KEYWORDS:

Bayes' theorem; first-trimester screening; mean arterial pressure; placental growth factor; pre-eclampsia; pregnancy-associated plasma protein-A; pyramid of pregnancy care; survival model; uterine artery Doppler

PMID:
28067011
DOI:
10.1002/uog.17399
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center